ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2234

Safety and Efficacy of Liposome Intra-Articular Injection in Moderate Knee Osteoarthritis.  a Prospective Randomized Double-Blinded Study

Leonid Kandel1, Yaniv Dolev2, Rachel Shimonov1, Gurion Rivkin1, Meir Liebergall1, Yoav Mattan1 and Xavier Chevalier3, 1Orthopedic Surgery Department, Hadassah Medical Center, Jerusalem, Israel, 2Moebius Medical Ltd., Tel Aviv, Israel, 3Department of Rheumatology Hopital Henri Mondor, Créteil, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Knee and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Osteoarthritis - Clinical Aspects: Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Bio-lubrication is a prerequisite for proper joint mobility and is crucial for prevention of degradative changes of the joint. Phospholipids are components of the synovial fluid and are known to serve as natural lubricants of cartilage surfaces. MM-II is a novel intra-articular bio-lubricant made of liposomes suspended in aqueous solution.
Purpose: to test the safety and effectiveness of intra-articular injection of MM-II in osteoarthritic patients compared with intra-articular hyaluronic acid (HA) up to 3 months of follow-up in a double-blind, randomized clinical study.
Methods: Patients with symptomatic unilateral knee OA with baseline pain on VAS of more than 40 mm and a stage 2-3 Kellgren Lawrence score on X-ray, were recruited. 40 patients were randomized into two groups of 20, to receive a single intra-articular injection of either MM-II or HA (Durolane®). Effectiveness measures included maximal global pain in the target knee, recorded by a 100mm VAS; WOMAC subscales; OMERACT OARSI responder criteria; PGA, PASS, PAE questions and consumption of paracetamol/acetaminophen, which was the only authorized rescue medication. Tolerability was assessed by local manifestation defined by an increase of at least 3 cm in knee circumference, measured at 2 cm above the upper border of the patella or local pain increase of more than 30 mm on a 100 mm VAS. Adverse events were recorded through 90-days of follow-up.
The study was FIM Exploratory non-powered, with descriptive statistics.
Results: All patients completed the study.
Results relating to WOMAC A pain, summarized in Figure 1, show a faster response with MM-II, with maximal effect observed on day 14, which was maintained over time and was associated with a statistically significant difference from baseline pain from day 7. In the HA group, the onset of pain relief was slower, with an improvement statistically significant change from baseline observed only on day 90.
Daily acetaminophen intake was lower in the MM-II group, with a reduction of more than 50% in the number of days and total dose of rescue medication consumption seen following MM-II administration, compared with HA injection.
The percent of responders to treatment according to the OMERAC-OARSI response criteria was 52.6, 66.7, 70 & 60 at the day 7, 14, 30 & 90 respectively compared to 30, 36.8, 25, 45 at the HA group (data not shown).
Local adverse events (inflammatory flare) were observed in one patient at day 3 in the MM-II group and in 4 pts at day 1, 1 pt at day 3, and 1 pt at day 7 in the HA group.
Patient’s Relative Change in WOMAC A in Target Knee over Time
https://acrabstracts.org/wp-content/uploads/2014/11/g149-1.png?noCache=16
*statistically significant difference from baseline
Conclusion: Intra-articular injections of MM-II were found to be safe and effective. The pain-reduction action was more rapid and sustained up to 3 months compared with HA. Larger randomized controlled trials are needed to confirm these encouraging results.


Disclosure:

L. Kandel,

MM-II ,

2;

Y. Dolev,

Stock options,

1;

R. Shimonov,
None;

G. Rivkin,
None;

M. Liebergall,
None;

Y. Mattan,
None;

X. Chevalier,

MM-II,

6.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-liposome-intra-articular-injection-in-moderate-knee-osteoarthritis-a-prospective-randomized-double-blinded-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences